Major Shareholder Sells 88,802 Shares of Werewolf Therapeutics

On November 24, 2023, Bioventures 2014 L.P. Mpm, a significant shareholder of Werewolf Therapeutics, Inc. (NASDAQ: HOWL), sold 88,802 shares of the company. The shares were transacted at an average price of $0.98, resulting in total proceeds of $87,025.96. Following this sale, Bioventures directly holds 5,168,303 shares of Werewolf Therapeutics, which are valued at approximately $5,064,936.94. This transaction marks a 1.69% decrease in their overall position in the company.

The details of this sale were filed with the U.S. Securities and Exchange Commission (SEC), as required for major shareholders owning 10% or more of a company’s shares. The SEC documentation can be accessed online for further details.

Current Stock Performance and Market Analysis

As of Thursday, November 30, 2023, Werewolf Therapeutics opened trading at $0.98. The company boasts a market capitalization of $47.42 million and reports a price-to-earnings ratio of -0.60, alongside a beta of 0.72. The stock has seen a 50-day moving average of $1.50 and a 200-day moving average of $1.34. Over the past year, the stock has fluctuated between a low of $0.60 and a high of $2.38.

Various analysts have recently provided insights into Werewolf Therapeutics’ stock. Citigroup reaffirmed its “market outperform” rating on November 12, while Weiss Ratings assigned a “sell (d-)” status on October 8. JMP Securities has adjusted its target price from $4.00 to $3.00, maintaining a “market outperform” rating. On November 21, Zacks Research downgraded the stock from a “strong-buy” to a “hold” rating. Most recently, Bank of America lowered its price target from $8.00 to $7.00, while keeping a “buy” rating. Overall, MarketBeat indicates that the average analyst rating for the stock is “Moderate Buy,” with a target price of $7.75.

Institutional Investors’ Engagement

Recent activity among institutional investors indicates a shift in confidence around Werewolf Therapeutics. Charles Schwab Investment Management Inc. increased its stake in the company by 33.2% during the first quarter, now holding 95,712 shares valued at approximately $93,000. Nuveen LLC also entered a new position worth around $71,000.

Additionally, MPM Asset Management LLC slightly increased its holdings by 0.6%, now owning 4,309,860 shares valued at approximately $4,189,000. MPM Bioimpact LLC also expanded its position by 0.9% during this period, bringing its total to 2,408,810 shares valued at about $2,341,000. Currently, approximately 64.84% of Werewolf Therapeutics’ stock is owned by institutional investors.

Werewolf Therapeutics is recognized for developing innovative therapeutics aimed at harnessing the body’s immune system to treat cancer. Utilizing its proprietary PREDATOR platform, the company designs conditionally activated molecules to enhance both adaptive and innate immunity, addressing the limitations commonly found in traditional proinflammatory immune therapies.

This recent transaction and the evolving analyst ratings reflect ongoing investor interest, underscoring the dynamic nature of the biopharmaceutical sector.